Welcome to our dedicated page for Rigel Pharmaceuticals news (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals stock.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) is a commercial stage biotechnology company based in South San Francisco, California, focused on therapies for hematologic disorders and cancer. This news page aggregates company announcements, financial updates and clinical data disclosures so readers can follow Rigel’s progress across its marketed products and development pipeline.
Rigel’s news flow frequently covers net product sales and total revenue from its hematology and oncology portfolio, including TAVALISSE (fostamatinib disodium hexahydrate), GAVRETO (pralsetinib) and REZLIDHIA (olutasidenib). Press releases detail quarterly and preliminary annual revenue, contract revenues from collaborations and government contracts, and commentary from management on commercial execution and financial performance.
Clinical and regulatory milestones are another major focus of Rigel’s news. Updates describe Phase 1b data for the investigational IRAK1/4 dual inhibitor prodrug R289 in relapsed or refractory lower-risk myelodysplastic syndrome, including safety, tolerability, pharmacokinetics and measures such as red blood cell transfusion independence. The company also reports on long-term and real-world data for REZLIDHIA in mIDH1 acute myeloid leukemia, and on presentations of pralsetinib data in RET fusion-positive solid tumors at oncology conferences.
Rigel’s releases highlight participation in scientific and investor meetings, such as the American Society of Hematology Annual Meeting and Exposition, the American Society of Clinical Oncology – Gastrointestinal Cancers Symposium, and major healthcare investment conferences. Corporate news can also include collaboration updates, such as developments in the ocadusertib program with Eli Lilly and Company, and stock-based inducement grants under Nasdaq Listing Rule 5635(c)(4).
Investors, clinicians and researchers can use this RIGL news feed to monitor earnings announcements, pipeline readouts, regulatory designations and conference presentations that shape the company’s trajectory in hematology and oncology.
Rigel Pharmaceuticals (Nasdaq: RIGL) will announce its first quarter 2023 financial results after market close on May 2, 2023. Following the results release, a live conference call will take place at 4:30 p.m. ET to discuss the outcomes and provide business updates. Interested participants can join the call at 877-407-3088 domestically or 201-389-0927 internationally, or access the webcast via the Rigel website. The archived recording will be available for 90 days post-call. Rigel is focused on developing therapies for hematologic disorders and cancer.
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) announced on April 6, 2023, the granting of 108,600 stock options to three non-executive employees as part of its Inducement Plan. This award is intended to incentivize employees entering employment with Rigel, aligning with NASDAQ Listing Rule 5635(c)(4). The options will vest over four years, with a one-year cliff before any options can be exercised. This move is aimed at enhancing employee retention and motivation within the company. Rigel, based in South San Francisco, focuses on developing innovative therapies for hematologic disorders and cancer.
Rigel Pharmaceuticals (RIGL) reported its financial results for Q4 2022, with total revenues of $51.3 million, including $21.9 million from TAVALISSE and $0.9 million from REZLIDHIA. The launch of REZLIDHIA, approved in December 2022, is progressing well, aided by its inclusion in NCCN Guidelines for AML. Rigel also received $20 million from Kissei due to TAVALISSE's approval in Japan. Despite a net income of $1.4 million in Q4 2022, Rigel faced increased total expenses of $49.2 million. For the full year, total revenues reached $120.2 million but resulted in a net loss of $58.6 million.
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) announced it will release its fourth quarter and full year 2022 financial results on March 7, 2023, after market close. Following the report, Rigel's senior management will host a live conference call and webcast at 4:30 p.m. ET to discuss the results and provide a business update. Investors can access the call by dialing a provided number or through the company's website. Rigel focuses on developing novel small molecule drugs for hematologic disorders and cancer.
Rigel Pharmaceuticals (NASDAQ: RIGL) announced positive results from its Phase 2 study of REZLIDHIA (olutasidenib) for treating mutant isocitrate dehydrogenase 1 (mIDH1) relapsed or refractory acute myeloid leukemia (R/R AML). The study, published in Blood Advances, included 153 adult patients, revealing a 35% complete remission plus complete remission with partial hematologic recovery (CR+CRh) rate. Notably, patients achieving CR+CRh had a median overall survival (OS) not yet reached, with 78% survival at 18 months. REZLIDHIA shows promise as a differentiated therapy, particularly following its recent FDA approval.
Rigel Pharmaceuticals (Nasdaq: RIGL) announced that REZLIDHIA (olutasidenib) has been included in the NCCN Clinical Practice Guidelines for acute myeloid leukemia (AML) as a recommended therapy for adult patients with relapsed/refractory AML carrying an IDH1 mutation. This recognition comes shortly after the FDA approved REZLIDHIA for adults with R/R AML in December 2022. The NCCN Guidelines are widely regarded as the standard for cancer care. CEO Raul Rodriguez expressed satisfaction with this prompt inclusion, underscoring the strength of REZLIDHIA's safety and efficacy data.
Rigel Pharmaceuticals (RIGL) announced FDA approval and commercial launch of REZLIDHIA for treating adult patients with relapsed or refractory AML with IDH1 mutations. Preliminary Q4 2022 revenue is expected to be approximately $51.3 million, driven by TAVALISSE sales of about $21.9 million. The company also recognized a $20 million milestone from Kissei for TAVALISSE’s approval in Japan. Rigel's cash position is $58.2 million, down from $125 million in 2021. Upcoming catalysts include ongoing clinical trials for R289 and R552, aimed at expanding their hematology-oncology portfolio.
FAQ
What is the current stock price of Rigel Pharmaceuticals (RIGL)?
What is the market cap of Rigel Pharmaceuticals (RIGL)?
